文献速递胸部肿瘤

完全切除及辅助化疗后pIIIA-N2非小细胞肺癌术后放疗的III期随机临床试验

Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.
PubMed 文献 · JAMA Oncol · 2021-01-01

PORT-C随机临床试验纳入394例完全切除并完成4周期铂类辅助化疗的pIIIA-N2非小细胞肺癌患者,随机分入术后放疗组(202例,50 Gy)或观察组(192例)。

核心结论

  • 在pIIIA-N2非小细胞肺癌完全切除及辅助化疗后患者中,术后放疗未改善无病生存期。
  • 需要进一步研究探索最可能从术后放疗中获益的患者人群。

研究设计与样本

  • 患者等比例随机分入术后放疗组(n=202)或观察组(n=192),术后放疗总剂量50 Gy。
  • 主要终点为无病生存期,次要终点包括总生存期、局部区域无复发生存期、无远处转移生存期和毒性反应。

主要发现

  • 共394例入组,364例符合分析条件,中位年龄55岁(范围25-70),男性202例(55.5%),女性162例(44.5%)。
  • 中位随访46.0个月(95%CI 41.9-51.4),报告230例DFS事件。

关键数值与推荐

  • 术后放疗总剂量为50 Gy。
  • 未观察到放疗相关4级或5级不良事件。

临床怎么用

  • 对于pIIIA-N2 NSCLC完全切除及辅助化疗后患者,术后放疗可考虑用于改善局部区域控制,但需权衡DFS获益的不确定性。
  • 应与患者充分讨论术后放疗的潜在获益(LRFS改善)与缺乏OS获益的证据。

局限性

  • 主要终点DFS在未调整分析中未达统计学显著,预设探索性分层分析结果需谨慎解读。
  • 研究未明确筛选出最能从术后放疗中获益的亚组人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The role of postoperative radiotherapy (PORT) has not been well defined in resected pIIIA-N2 non-small cell lung cancer (NSCLC). OBJECTIVE: To evaluate the effect of PORT using modern techniques on survival and safety in patients with pIIIA-N2 NSCLC after complete resection and adjuvant chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: The PORT-C randomized clinical trial was conducted in 394 patients with pIIIA-N2 NSCLC treated with complete resection and 4 cycles of platinum-based chemotherapy between January 2009 and December 2017. Data were analyzed between March 2019 and December 2020. INTERVENTIONS: Patients were randomized equally into the PORT arm (n = 202) or the observation arm (n = 192). The total dose of PORT was 50 Gy. MAIN OUTCOMES AND MEASURES: The primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS), locoregional recurrence-free survival (LRFS), distant metastasis-free survival, and toxic effects. RESULTS: In total, 394 patients were enrolled and 364 were eligible, with a median (range) age of 55 (25-70) years. There were 202 (55.5%) male and 162 (44.5%) female patients. The median follow-up was 46.0 (95% CI, 41.9-51.4) months, and 230 DFS events were reported. There were 184 patients in the PORT arm and 180 patients in the observation arm. The 3-year DFS rates were 40.5% with PORT vs 32.7% with observation (median, 22.1 vs 18.6 months), and the difference in DFS was not statistically significant without adjustment (hazard ratio [HR], 0.84; 95% CI, 0.65-1.09; P = .20), though it was significant with preplanned yet exploratory analysis (stratified analysis by the number of detected lymph nodes and positive lymph nodes, HR, 0.75; log-rank P = .04). The 3-year OS rates were 78.3% vs 82.8% (HR, 1.02; P = .93), and LRFS was 66.5% vs 59.7% (HR, 0.71; 95% CI, 0.51-0.97; P = .03), respectively. For 310 per-protocol patients (140 with PORT and 170 with observation), PORT significantly improved DFS (42.8% vs 30.6%; HR, 0.75; 95% CI, 0.57-1.00; P = .05) but not OS (HR, 0.83; 95% CI, 0.53-1.30; P = .41). The 3-year local recurrence only rates were 9.5% and 18.3% in the 2 arms, respectively (Fine-Gray HR, 0.55; Gray test P = .04). No radiotherapy-related grade 4 or 5 adverse event was observed. CONCLUSIONS AND RELEVANCE: In this phase 3 randomized clinical trial of patients with pIIIA-N2 NSCLC after complete resection and adjuvant chemotherapy, PORT did not improve DFS. Further studies exploring patients who might best benefit from PORT are needed. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00880971.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Hui Z, Men Y, Hu C, et al. Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial. JAMA Oncol. 2021. PMID: 34165501. doi:10.1001/jamaoncol.2021.1910

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。